Recent blog posts
Potent "bone-protecting drugs" - RANKL inhibitors
Potent "bone-protecting drugs" - RANKL inhibitors
1 October 2023
RANKL, or Receptor Activator of Nuclear Factor Kappa-B Ligand, is a crucial protein involved in the regulation of bone metabolism in the human body.
Read →
Proteasome Inhibitors Initiate a New Treatment Regime for Multiple Myeloma
Proteasome Inhibitors Initiate a New Treatment Regime for Multiple Myeloma
1 October 2023
Proteasomes are a key component of the ubiquitin-proteasome pathway, a central platform for recycling proteins involved in crucial cellular processes, including cell cycle progression, DNA repair, and transcription.
Read →
A Rising Force in Tumor Immunotherapy: PD-1 Inhibitors
A Rising Force in Tumor Immunotherapy: PD-1 Inhibitors
30 September 2023
Programmed cell death protein-1 (PD-1) is an important immune inhibitory molecule, belonging to the immunoglobulin superfamily.
Read →
Analysis on the Research Progress of PDE4 Inhibitors
Analysis on the Research Progress of PDE4 Inhibitors
30 September 2023
Phosphodiesterase 4 (PDE4) is an enzyme found in various tissues of the human body, including the immune cells, brain, and lungs.
Read →
Analysis on the Clinical Research Progress of Prostaglandin Synthases Inhibitors
Analysis on the Clinical Research Progress of Prostaglandin Synthases Inhibitors
30 September 2023
Prostaglandin synthases are enzymes that play a crucial role in the human body by catalyzing the synthesis of prostaglandins.
Read →
Advances in Clinical Research on PPAR Agonists
Advances in Clinical Research on PPAR Agonists
30 September 2023
PPAR, or peroxisome proliferator-activated receptor, is a group of nuclear receptor proteins found in the human body.
Read →
Analysis on the Research Progress of Protease inhibitors
Analysis on the Research Progress of Protease inhibitors
30 September 2023
Proteases are enzymes that play a crucial role in the human body by breaking down proteins into smaller peptides or amino acids.
Read →
New Epigenetic Drug Targets: PRMT5 Inhibitors
New Epigenetic Drug Targets: PRMT5 Inhibitors
30 September 2023
PRMT5 expression is associated with a poor prognosis in tumor progression and metastasis.
Read →
Advances in Clinical Research on PARP1 inhibitors
Advances in Clinical Research on PARP1 inhibitors
30 September 2023
PARP1 is the most prominent member of the PARP family, accounting for 80%-90% of the enzyme activity, and is a key player in DNA damage repair.
Read →
Analysis on the Clinical Research Progress of PDL1 inhibitors
Analysis on the Clinical Research Progress of PDL1 inhibitors
30 September 2023
Programmed death-ligand 1 (PD-L1) is a protein found on the surface of certain cells in the human body, including immune cells and some cancer cells.
Read →
Cardiovascular Disease Treatment Drug - PDE3 Inhibitors
Cardiovascular Disease Treatment Drug - PDE3 Inhibitors
30 September 2023
PDE3 has the ability to hydrolyze both cAMP and cGMP, but its ability to hydrolyze cAMP is about ten times that of cGMP.
Read →
Analysis on the Clinical Research Progress of CYP2C9 Inhibitors
Analysis on the Clinical Research Progress of CYP2C9 Inhibitors
27 September 2023
CYP2C9 is a member of the Cytochrome P450 superfamily of enzymes that primarily metabolize drugs in the human body.
Read →